Endoscopic botulinum toxin injection for cricopharyngeal dysphagia.

Ann Otol Rhinol Laryngol

Department of Otolaryngology-Head and Neck Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.

Published: October 2002

Twelve patients underwent 17 endoscopic injections of botulinum toxin type A in the cricopharyngeus muscle for the treatment of dysphagia and cricopharyngeal spasm over a 3-year period. The patient's charts were reviewed. Preoperative and postoperative symptoms, examination, and swallowing studies were reviewed. Eleven of the 12 patients had improvement in their symptoms, which lasted for a mean of 3.8 months. Two patients elected cricopharyngeal myotomy for permanent correction of their dysphagia. There was 1 case of postoperative neck cellulitis in an immunocompromised patient undergoing simultaneous excision of a thyroglossal duct cyst. We conclude that endoscopic injection of botulinum toxin is a relatively safe and viable technique for the treatment of dysphagia associated with cricopharyngeal spasm. It requires simple tools readily available to otolaryngologists. Larger, prospective controlled studies are necessary to establish its effectiveness and role in the management of this condition.

Download full-text PDF

Source
http://dx.doi.org/10.1177/000348940211101002DOI Listing

Publication Analysis

Top Keywords

botulinum toxin
12
treatment dysphagia
8
cricopharyngeal spasm
8
endoscopic botulinum
4
toxin injection
4
cricopharyngeal
4
injection cricopharyngeal
4
dysphagia
4
cricopharyngeal dysphagia
4
dysphagia twelve
4

Similar Publications

Background: Spasticity is an upper motor neuron syndrome that exacerbates motor paralysis and is rarely associated with pain. This report elucidates the management of drug-resistant pain attributed to an adolescent brain tumor using botulinum therapy.

Case Presentation: A 15-year-old female patient experienced dizziness, developed muscle weakness in her upper extremities, and was diagnosed with diffuse glioblastoma of the pons.

View Article and Find Full Text PDF

Objectives: To evaluate the cost-utility of botulinum toxin A (BoNT-A) for treating upper limb (UL) and lower limb (LL) post-stroke spasticity.

Design: Using a Markov model, adopting a societal perspective and a lifetime horizon with a 3% annual discount rate, the cost-utility analysis was conducted to compare BoNT-A combined with standard of care (SoC) with SoC alone. Costs, utilities, transitional probabilities and treatment efficacy were derived from 5-year retrospective data from tertiary hospitals and meta-analysis.

View Article and Find Full Text PDF

Background: Botulinum toxin is a well-established treatment for dynamic glabellar lines. Glabellar contraction patterns were described previously in the general Brazilian population and also among Koreans, Chinese, and Indian individuals. So far, no study has addressed glabellar contraction "patterns" in Black subjects.

View Article and Find Full Text PDF

Purpose Of Review: This narrative review aims to report upon the existing treatment evidence and strategies for managing lower urinary tract symptoms (LUTS) during treatment, including transurethral resection and intravesical therapy. This review also attempts to examine novel approaches to mitigate treatment-related lower urinary tract symptoms and improve treatment adherence.

Recent Findings: There is sparse but promising evidence in improving LUTS secondary to intravesical therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!